Table 2 DFS of stage IV patients with CRCLM (Cohort I).
From: Correlations between TBL1XR1 and recurrence of colorectal cancer
Variables | Cases (n = 47) | 3-year DFS (%) | DFS (months) Mean ± S.D. | P value |
|---|---|---|---|---|
Gender | 0.515 | |||
Female | 20 | 37.0% | 31.2 ± 4.9 | |
Male | 27 | 53.0% | 35.5 ± 4.3 | |
Age (year) | 0.672 | |||
<60 | 17 | 62.0% | 37.1 ± 4.5 | |
≥60 | 30 | 38.5% | 32.1 ± 4.3 | |
Primary tumor location | 0.082 | |||
Colon | 34 | 48.5% | 36.6 ± 3.9 | |
Rectum | 13 | 41.0% | 26.2 ± 4.8 | |
Primary tumor differentiation | 0.332 | |||
Poor | 15 | 59.3% | 38.5 ± 5.8 | |
Well/Moderate | 32 | 38.3% | 30.9 ± 3.8 | |
CRCLM distribution | 0.043* | |||
Unilobar | 34 | 53.1% | 37.6 ± 3.5 | |
Bilobar | 13 | 25.4% | 22.9 ± 6.3 | |
No. of CRCLM | 0.253 | |||
<3 | 34 | 50.7% | 36.2 ± 3.5 | |
≥3 | 13 | 32.1% | 28.0 ± 7.9 | |
Resection Margin | 0.031* | |||
R0 | 39 | 50.4% | 36.1 ± 3.4 | |
R1 | 8 | 0.0% | 15.3 ± 2.6 | |
Adjunctive chemotherapy | 0.007* | |||
Yes | 37 | 52.7% | 37.4 ± 3.6 | |
No | 10 | 17.1% | 19.3 ± 4.4 | |
TBL1XR1 expression in CRC | 0.014* | |||
Low | 20 | 65.0% | 43.7 ± 4.7 | |
High | 27 | 30.9% | 25.9 ± 3.6 | |
TBL1XR1 expression in CRCLM | 0.041* | |||
Low | 13 | 49.5% | 42.5 ± 7.0 | |
High | 34 | 44.0% | 30.1 ± 3.3 |
